Details for New Drug Application (NDA): 210449
✉ Email this page to a colleague
NDA 210449 describes CANAGLIFLOZIN, which is a drug marketed by Apotex and Aurobindo Pharma Ltd and is included in two NDAs. Additional details are available on the CANAGLIFLOZIN profile page.
The generic ingredient in CANAGLIFLOZIN is canagliflozin. There are twenty-one drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the canagliflozin profile page.
The generic ingredient in CANAGLIFLOZIN is canagliflozin. There are twenty-one drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the canagliflozin profile page.
Summary for 210449
| Tradename: | CANAGLIFLOZIN |
| Applicant: | Apotex |
| Ingredient: | canagliflozin |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 210449
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 100MG | ||||
| Approval Date: | Apr 14, 2026 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 300MG | ||||
| Approval Date: | Apr 14, 2026 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
